Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced HER2+Breast Cancer × pertuzumab × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 24 Neoplasms 5 Neoplasm Metastasis 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Inflammatory Breast Neoplasms 2 HER2-positive Early Breast Cancer 2 HER2-positive Breast Cancer 2 Endometrial Neoplasms 2 Colonic Neoplasms 2 Anatomic Stage I Breast Cancer AJCC v8 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumors 1 Solid Cancer 1 Resectable HER2-positive Breast Cancer 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Patient Preference 1 Pathologic Complete Response 1 Meningeal Neoplasms 1 Meningeal Carcinomatosis 1 Malignant Solid Neoplasm 1 Liver Neoplasms 1 Hemangiosarcoma 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Early-stage Breast Cancer 1 Gastrointestinal Neoplasms 1 Early-stage or Locally Advanced HER2-positive Breast Cancer 1

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04208178 2026-02-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡